<DOC>
	<DOCNO>NCT00000419</DOCNO>
	<brief_summary>Safety Estrogens Lupus Erythematosus - National Assessment ( SELENA ) study test whether postmenopausal woman systemic lupus erythematosus ( SLE , lupus ) safely use hormone estrogen . In part study , look effect estrogen replacement therapy activity severity disease woman SLE .</brief_summary>
	<brief_title>Safety Estrogens Lupus : Hormone Replacement Therapy</brief_title>
	<detailed_description>This study test effect exogenous female hormone disease activity severity woman systemic lupus erythematosus ( SLE ) . Physicians generally prescribe hormone replacement therapy ( HRT ) woman SLE widely hold view treatment activate SLE . This practice base great incidence SLE woman men , biologic abnormality estrogen metabolism , murine model lupus , several anecdote patient disease flare receive exogenous hormone , single retrospective study patient preexist renal disease . By contrast , recent retrospective study suggest rate flare significantly increase patient take HRT . We examine , multicenter , randomize , double-blind , placebo-controlled trial , effect hormonal replacement conjugate estrogens disease activity postmenopausal woman SLE . We recruit patient clinic private practice include 4,000 woman SLE , belong minority group . We give patient hormone 1 year . NOTE : This trial terminate August 2002 upon recommendation Data Safety Monitoring Board ( DSMB ) , base finding WHI Trial . Study subject discontinue study drug continue followup visit study doctor May 2003</detailed_description>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Estrogens , Conjugated ( USP )</mesh_term>
	<mesh_term>Medroxyprogesterone Acetate</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<criteria>Female Unequivocal diagnosis SLE Inactive disease stable 0.5 mg/kg/day less prednisone Chemical evidence menopause stop period least 6 month Blood pressure &gt; 145/95 three occasion Deep vein , arterial thrombosis pulmonary embolus GPL &gt; 40 ; MPL &gt; 40 ; APL &gt; 50 ; dRVVT &gt; 37 sec APL antibody syndrome ever Gynecologic breast cancer Hepatic dysfunction liver tumor Diabetes mellitus ( NOT due steroid ) vascular disease Congenital hyperlipidemia Complicated migraine Severe disease activity ( SLEDAI &gt; 12 ) Increase SLEDAI &gt; 2 point 3 month Unexplained vaginal bleeding Use estrogen ( HRT OCP ) &gt; 1 month time SLE diagnosis FSH &lt; 40 Premenopausal myocardial infarction</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>SLE</keyword>
	<keyword>SELENA</keyword>
	<keyword>Estrogen Replacement Therapy ( ERT )</keyword>
	<keyword>Postmenopause</keyword>
	<keyword>Osteoporosis</keyword>
	<keyword>Estrogens</keyword>
	<keyword>Steroids</keyword>
	<keyword>Progestin</keyword>
	<keyword>Placebo</keyword>
</DOC>